Skip to content

Study · Case report or series · n = 1 · 2025

4 results

Hypersensitivity to liraglutide: A case report.

Marino-Fernández AG, García-Gutiérrez I, Alonso Juaristi S, López Gutiérrez J, Tawfiq Piedad M, Guerrero Sotelo ÁL, Albarracín Contreras ÁJ, Ortiz Aljaro P, Rodríguez Fernández F

Asia Pacific allergy14 Jun 2024Cited by 1 (Europe PMC)

PMID40718123 (opens in a new tab)PMCIDPMC12289086 (opens in a new tab)DOI10.5415/apallergy.0000000000000149 (opens in a new tab)PepBankPUB-40718123
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

Saxenda (liraglutide) is approved for the treatment of type 2 diabetes mellitus and chronic weight management in adults with obesity. We present the case of a 44-year-old woman with grade 2 obesity who was treated with liraglutide for weight reduction, initially well-tolerated. Despite a brief pause in liraglutide treatment for 5 days due to hospitalization, she developed, after the reintroduction of this treatment, a localized reaction characterized by maculopapular erythema and pruritus at the injection site. Skin tests revealed an acute positive reaction to liraglutide. Literature suggests variability in allergic reactions among glucagon-like peptide-1 receptor agonists, highlighting the need for further research. Our case underscores the importance of individualized management in treating adverse reactions to liraglutide in obese patients without type 2 diabetes mellitus.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In one woman with obesity, liraglutide reintroduction was followed by maculopapular erythema at the injection site.

    In plain wordsIn one woman with obesity, liraglutide reintroduction was followed by injection-site redness.

    Peptide
    Liraglutide
    Outcome
    Not applicablemaculopapular erythema at injection site
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Despite a brief pause in liraglutide treatment for 5 days due to hospitalization, she developed, after the reintroduction of this treatment, a localized reaction characterized by maculopapular erythema and pruritus at the injection site.
    1 context sentence
    Summary · context
    We present the case of a 44-year-old woman with grade 2 obesity who was treated with liraglutide for weight reduction, initially well-tolerated.
  2. 02HumanCase report or seriesSafety outcome

    In one woman with obesity, liraglutide reintroduction was followed by pruritus at the injection site.

    In plain wordsIn one woman with obesity, liraglutide reintroduction was followed by an itchy injection site.

    Peptide
    Liraglutide
    Outcome
    Not applicableinjection-site pruritus
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Despite a brief pause in liraglutide treatment for 5 days due to hospitalization, she developed, after the reintroduction of this treatment, a localized reaction characterized by maculopapular erythema and pruritus at the injection site.
    1 context sentence
    Summary · context
    We present the case of a 44-year-old woman with grade 2 obesity who was treated with liraglutide for weight reduction, initially well-tolerated.
  3. 03HumanCase report or seriesSafety outcome

    In one woman with obesity, skin tests showed an acute positive reaction to liraglutide.

    In plain wordsIn one woman with obesity, skin tests showed an acute reaction to liraglutide.

    Peptide
    Liraglutide
    Outcome
    Not applicableacute skin-test reaction
    Study

    n = 1

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Skin tests revealed an acute positive reaction to liraglutide.
    1 context sentence
    Summary · context
    We present the case of a 44-year-old woman with grade 2 obesity who was treated with liraglutide for weight reduction, initially well-tolerated.
  4. 04HumanCase report or seriesSafety outcome

    In one 44-year-old woman with grade 2 obesity, liraglutide for weight reduction was initially well tolerated before later interruption and localized hypersensitivity after reintroduction.

    In plain wordsIn one woman with obesity, liraglutide was initially tolerated before a later interruption and reaction after restarting.

    Peptide
    Liraglutide
    Outcome
    Not applicableInitial treatment tolerability
    Study

    n = 1

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We present the case of a 44-year-old woman with grade 2 obesity who was treated with liraglutide for weight reduction, initially well-tolerated.
    1 context sentence
    Summary · context
    Despite a brief pause in liraglutide treatment for 5 days due to hospitalization, she developed, after the reintroduction of this treatment, a localized reaction characterized by maculopapular erythema and pruritus at the injection site.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.